Validus Pharmaceuticals Overview
- Founded
-
2007
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Debt
- Financing Rounds
-
2
- Investments
-
1
Validus Pharmaceuticals General Information
Description
Operator of a specialty pharmaceutical company intended to bring trusted brands to life. The company focuses on the acquisition, reformulation and commercialization of prescription products that will satisfy unmet clinical needs in specialty therapeutic areas, thereby enabling doctors and physicians to guide their patients to learn more about their diseases.
Contact Information
Website
www.validuspharma.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Primary Office
- 90 East Halsey Road
- Suite 210
- Parsippany, NJ 07054
- United States
+1 (866) 000-0000
Validus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Validus Pharmaceuticals Patents
Validus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160067187-A1 | Methods for treating or preventing migraines | Inactive | 28-Sep-2005 | 00000000 | |
| CA-2452588-A1 | Methods for the treatment of bipolar disorder using carbamazepine | Active | 08-Dec-2003 | 00000000000 | |
| CA-2452588-C | Methods for the treatment of bipolar disorder using carbamazepine | Active | 08-Dec-2003 | 00000000000 | |
| US-6977253-B2 | In extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | Active | 08-Dec-2003 | 00000000000 | 0 |
| US-20050124601-A1 | In extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | Active | 08-Dec-2003 | A61K31/5415 |
Validus Pharmaceuticals Executive Team (5)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| John Kinney | Chief Executive Officer | ||
| Emile Williams | Chief Operating Officer | ||
| Richard Guarino MD | Vice President, Medical & Regulatory Affairs |
Validus Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Validus Pharmaceuticals Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 (00 00 | 10-Dec-2015 | 0000000000 | Pharmaceuticals |